{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:01:02Z","timestamp":1787796062498,"version":"build-2784847793"},"reference-count":11,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background<\/jats:title>\n<jats:p>Though higher doses of terbinafine are often prescribed to treat dermatophyte infections, it is unknown if such doses are more effective than the conventional dose because comparative data are unavailable.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Aim<\/jats:title>\n<jats:p>To compare the efficacy and safety of a once-daily dose of oral terbinafine 250 mg with 500 mg along with topical clotrimazole in the treatment of tinea infections.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A randomised, assessor-blinded, comparative study was carried out. Each group of subjects were administered either 250 mg or 500 mg oral terbinafine once daily for four weeks, along with topical clotrimazole. Clinical improvement was assessed after two weeks and again after four weeks from treatment initiation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Result<\/jats:title>\n<jats:p>A total of 60 patients with tinea corporis and cruris were randomised into two groups receiving either 250 mg (group A) or 500 mg (group B) oral terbinafine, along with clotrimazole cream in both groups. Baseline clinical parameters such as lesional activity (papules, vesicles and pustules), degree of erythema, scaling and severity of itching were comparable between both treatment arms. At the first and second follow-ups, no significant differences were found in the clinical parameters between the two groups. At the end of two weeks 13.8% of group A and 14.3% of group B and after 4 weeks 25.9% of group A and 33.3% of group B participants became KOH negative (<jats:italic>P<\/jats:italic> = 1.00 and 0.76, respectively). No significant difference in culture negativity was reported at the end of therapy (four weeks) between the two treatment arms (<jats:italic>P<\/jats:italic> = 0.78). Overall cure rates were 20% and 33.3% in the two treatment arms respectively at the end of the study (<jats:italic>P<\/jats:italic> = 0.82).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Oral terbinafine 250 mg daily yielded a poor cure rate in tinea cruris and corporis after 4 weeks of treatment and an increased dose of 500 mg did not have any additional benefit.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_74_2022","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:12:43Z","timestamp":1671005563000},"page":"665-671","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of 250 mg versus 500 mg oral terbinafine in the treatment of tinea corporis and cruris: A randomised, assessor-blinded comparative study"],"prefix":"10.25259","volume":"89","author":[{"given":"Niharika Ranjan","family":"Lal","sequence":"first","affiliation":[{"name":"Department of Dermatology, ESI-PGIMSR & ESIC Medical College, Joka, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyendu","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Raiganj Government Medical College, Raiganj, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abanti","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roumi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ESI-PGIMSR & ESIC Medical College, Joka, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, BPS Government Medical College, Sonipat, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"10.25259\/IJDVL_74_2022\/ref-1","first-page":"1807","volume-title":"Fitzpatrick\u2019s Dermatology in General Medicine","author":"Verma","year":"2008","edition":"7th ed."},{"key":"10.25259\/IJDVL_74_2022\/ref-2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/2229-5178.178100","article-title":"The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive?","volume":"7","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_74_2022\/ref-3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4103\/ijd.IJD_191_17","article-title":"Efficacy and safety of terbinafine 500 mg once daily in patients with dermatophytosis","volume":"62","author":"Babu","year":"2017","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_74_2022\/ref-4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4103\/ijd.IJD_548_19","article-title":"Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labelled trial with clinico-mycological correlation","volume":"65","author":"Singh","year":"2020","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_74_2022\/ref-5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/ijd.IJD_206_17","article-title":"The great Indian epidemic of superficial dermatophytosis: An appraisal","volume":"62","author":"Verma","year":"2017","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_74_2022\/ref-6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/idoj.idoj_62_19","article-title":"Clinicomycological study of dermatophytosis in a tertiary care hospital in eastern India: A cross-sectional study","volume":"11","author":"Singh","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_74_2022\/ref-7","first-page":"259","article-title":"Clinico-mycological study of dermatophytosis in Calicut","volume":"68","author":"Bindu","year":"2002","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_74_2022\/ref-8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/ijd.ijd_203_19","article-title":"The current Indian epidemic of dermatophytosis: A study on causative agents and sensitivity patterns","volume":"65","author":"Das","year":"2020","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_74_2022\/ref-9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/ijp.IJP_578_17","article-title":"Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study","volume":"51","author":"Bhatia","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"10.25259\/IJDVL_74_2022\/ref-10","doi-asserted-by":"publisher","first-page":"e02522","DOI":"10.1128\/AAC.02522-17","article-title":"Mutation in the Squalene Epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance","volume":"62","author":"Rudramurthy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJDVL_74_2022\/ref-11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4103\/ijd.ijd_435_17","article-title":"Rational for drug dosimetry and duration of terbinafine in the context of recalcitrant dermatophytosis: Is 500 mg better than 250 mg OD or BD?","volume":"62","author":"Sardana","year":"2017","journal-title":"Indian J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-250-mg-versus-500-mg-oral-terbinafine-in-the-treatment-of-tinea-corporis-and-cruris-a-randomised-assessor-blinded-comparative-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-250-mg-versus-500-mg-oral-terbinafine-in-the-treatment-of-tinea-corporis-and-cruris-a-randomised-assessor-blinded-comparative-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:34:03Z","timestamp":1693197243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-250-mg-versus-500-mg-oral-terbinafine-in-the-treatment-of-tinea-corporis-and-cruris-a-randomised-assessor-blinded-comparative-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":11,"alternative-id":["10.25259\/IJDVL_74_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_74_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"665"}}